CJC-1295 Without DAC (Modified GRF 1-29) 5 mg

CJC-1295 Without DAC (Modified GRF 1-29) 5 mg

GHRH Analogue Research Peptide

CJC-1295 Without DAC 5 mg | Research-Grade ≥99% Purity | HKPEPTIDE WORLDWIDE

Reviewed by: HKPEPTIDE WORLDWIDE Research Team | Last Updated: 2026-08-08 | Document ID: HKPW-cjc-nodac-5mg-v2.0

1. Product Identity & Specifications

CJC-1295 Without DAC 5 mg is the mid-scale research configuration in HKPEPTIDE WORLDWIDE’s comprehensive CJC-1295 product family. Optimized for multi-point dose-response curves, pulsatile GH secretion modeling, comparative pharmacology experiments, and protocols requiring sufficient material for replicate measurements across multiple experimental arms, the 5 mg format provides the ideal balance between experimental capacity and cost efficiency. This short-acting GHRH analogue — a tetra-substituted GRF(1-29) amide — is the definitive research tool for studies requiring rapid-clearance pharmacokinetics and physiological pulsatile receptor activation patterns.

ParameterSpecification
Product NameCJC-1295 Without DAC (Modified GRF 1-29)
Parent MoleculeGRF(1-29) amide (Sermorelin, CAS 83930-13-6)
Molecular FormulaC₁₅₂H₂₅₂N₄₄O₄₂S
Molecular Weight~3367 Da
Amino Acid SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
Key ModificationsD-Ala² (DPP-4 resistance); Gln⁸, Ala¹⁵, Leu²⁷ (oxidation/metabolic stability); C-terminal amidation
Vial Content5 mg net peptide
AppearanceWhite to off-white lyophilized powder
Purity≥99% by HPLC
SolubilitySoluble in aqueous buffers (pH 7.4); DMSO for stock solutions
Plasma Half-Life~30 minutes (rapid renal clearance)
GHRH-R Binding AffinityIC₅₀ ~1.2 nM (competitive displacement of [¹²⁵I]-GRF)
Storage (Lyophilized)-20°C, protected from light and moisture
Storage (Reconstituted)2–8°C, use within 30 days
Product GradeResearch Use Only (RUO)
Peptide Content≥85% (net peptide basis)

2. Research Background

CJC-1295 represents a significant engineering achievement in the development of long-acting GHRH analogues. The story begins with native GHRH(1-44)-NH₂, a 44-amino acid hypothalamic peptide first isolated and characterized independently by two groups in 1982 from human pancreatic tumors that caused acromegaly (Rivier et al., 1982; Guillemin et al., 1982). The biologically active core was rapidly identified as the N-terminal 29 amino acids — GRF(1-29)-NH₂ — which retained full receptor activation potency while eliminating unnecessary C-terminal sequence. This truncated analogue, later named Sermorelin (CAS 83930-13-6), became the first GHRH analogue to enter clinical development for diagnostic evaluation of growth hormone deficiency (PMID: 2870820).

However, native GRF(1-29)-NH₂ suffered from two critical limitations that restricted its research utility: susceptibility to rapid proteolytic degradation (plasma half-life <10 minutes) and potential for methionine oxidation at position 27. ConjuChem Biotechnologies addressed these limitations through rational peptide engineering, creating a series of tetra-substituted GRF(1-29) analogues. The “CJC-1295 core” incorporates four strategic amino acid substitutions: D-Ala at position 2 for DPP-4 resistance, Gln at position 8 (replacing Asn) to eliminate a potential deamidation site, Ala at position 15 (replacing Gly) for enhanced helical stability, and Leu at position 27 (replacing Met) to eliminate the oxidation-sensitive methionine residue (PMID: 16984234).

The critical bifurcation in the CJC-1295 family arises from the presence or absence of the Drug Affinity Complex (DAC) moiety. CJC-1295 Without DAC is the unmodified tetra-substituted GRF(1-29) core — a short-acting GHRH receptor agonist with a plasma half-life of approximately 30 minutes. This rapid clearance profile makes it the preferred research tool for modeling physiological pulsatile GH secretion patterns, investigating GHRH receptor desensitization kinetics, and studying the temporal dynamics of somatotroph signaling without the confounding influence of sustained receptor occupancy. In contrast, CJC-1295 With DAC incorporates a maleimidopropionic acid linker conjugated to a reactive thiol group at Lys²⁰, enabling covalent, irreversible binding to serum albumin. This modification extends the half-life to approximately 8 days but fundamentally alters the pharmacokinetic properties (PMID: 16984234).

For the research community, CJC-1295 Without DAC serves as an essential reference standard — the “clean” comparator compound for discriminating between receptor-level pharmacological effects and pharmacokinetic effects mediated by the DAC modification. Its well-characterized receptor pharmacology, precisely defined molecular structure, and rapid clearance kinetics make it indispensable for GHRH receptor signaling studies, pulse-frequency modeling, and structure-activity relationship investigations.

3. Molecular Mechanisms

3.1 GHRH Receptor Activation and cAMP Signaling

CJC-1295 Without DAC binds with high affinity (IC₅₀ ~1.2 nM) to the Growth Hormone-Releasing Hormone receptor (GHRH-R), a class B (secretin-like) G-protein-coupled receptor predominantly expressed on somatotroph cells of the anterior pituitary gland. The GHRH-R is a 423-amino acid protein with a characteristic N-terminal extracellular domain, seven-transmembrane helical core, and intracellular C-terminal tail that couples primarily to the stimulatory Gαs protein.

Ligand binding induces a conformational transition that promotes GDP-GTP exchange on Gαs, leading to dissociation of the Gαs-GTP subunit from the Gβγ heterodimer. The free Gαs-GTP activates membrane-associated adenylate cyclase, catalyzing the conversion of ATP to cyclic adenosine monophosphate (cAMP). Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor cAMP response element-binding protein (CREB) at Ser¹³³, enabling its translocation to the nucleus and binding to cAMP response elements (CRE) in the promoter regions of target genes — including the growth hormone (GH1) gene itself (PMID: 1310906).

3.2 Calcium Signaling and GH Exocytosis

In parallel with the cAMP-PKA-CREB axis, GHRH-R activation opens voltage-gated L-type calcium channels on the somatotroph plasma membrane, generating a rapid influx of extracellular Ca²⁺. This calcium transient triggers the exocytotic fusion of growth hormone-containing secretory vesicles with the plasma membrane — the immediate mechanism of pulsatile GH release. The cAMP and calcium pathways converge synergistically: PKA-mediated phosphorylation potentiates L-type channel opening, while calcium-calmodulin stimulates additional kinases that enhance vesicle docking and fusion protein activity (PMID: 10385398).

3.3 GH Pulse Amplitude and Frequency Encoding

The short ~30-minute half-life of CJC-1295 Without DAC is a feature rather than a limitation for researchers studying the physiological dynamics of GH secretion. Native hypothalamic GHRH is released in discrete pulses approximately every 3-4 hours, with each pulse lasting only minutes before the peptide is cleared by plasma proteases and renal filtration. The 5 mg format enables the design of protocols that systematically vary pulse amplitude, frequency, and interpulse interval — the three critical parameters encoding the GH secretory signal. This makes CJC-1295 Without DAC the superior tool for investigating the molecular mechanisms underlying GH pulsatility — a phenomenon essential for normal growth, metabolism, and tissue repair that is fundamentally lost with sustained-receptor-occupancy compounds (PMID: 11250971).

3.4 Receptor Desensitization and Internalization

Prolonged GHRH-R activation produces receptor desensitization through GRK-mediated phosphorylation and β-arrestin recruitment, followed by clathrin-mediated endocytosis and lysosomal degradation. The rapid clearance of CJC-1295 Without DAC prevents sustained receptor occupancy, allowing researchers to study the full cycle of activation, desensitization, internalization, and receptor recycling without the confounding influence of persistent ligand exposure. This property is particularly valuable for research into GHRH-R trafficking dynamics and the mechanisms governing resensitization of the somatotroph axis (PMID: 16804053).

4. Research Applications & Focus Areas

The 5 mg CJC-1295 Without DAC configuration is ideally suited for:

  • Multi-Point Dose-Response Curves: Systematic determination of EC₅₀ values across 8-12 concentration points (10⁻¹² to 10⁻⁶ M) with triplicate measurements in primary anterior pituitary cell cultures
  • Pulse Frequency-Response Studies: Perifusion systems designed to compare GH secretory output under varying GHRH pulse frequencies (e.g., every 30, 60, 90, 120 minutes) at constant pulse amplitude
  • Comparative Pharmacology: Direct side-by-side benchmarking of CJC-1295 Without DAC against native GRF(1-29), Sermorelin, CJC-1295 With DAC, and other GHRH analogues in parallel assay plates
  • Signaling Bias Analysis: Quantification of Gαs versus β-arrestin signaling using BRET-based biosensors in GHRH-R-expressing HEK293 cells
  • Receptor Desensitization Kinetics: Time-course experiments measuring cAMP attenuation and receptor internalization following single or repeated ligand exposures
  • Combination Studies with GHS-R Agonists: Synergistic interaction analysis with GHRP-2, GHRP-6, or Ipamorelin to quantify functional cooperativity between GHRH-R and GHS-R1a signaling pathways

5. Quality Control & Analytical Specifications

Every lot of CJC-1295 Without DAC 5 mg undergoes a rigorous multi-tier quality control program:

TestMethodAcceptance Criteria
PurityRP-HPLC (C18 column, 214 nm)≥99.0%
Molecular Weight ConfirmationESI-MS / MALDI-TOF MS3367 ± 1.0 Da
Peptide ContentAmino Acid Analysis (AAA)≥85.0%
Trifluoroacetate (TFA) ContentIon Chromatography≤1.0%
Water ContentKarl Fischer Titration≤5.0%
EndotoxinLAL Kinetic Chromogenic≤1.0 EU/mg
AppearanceVisual InspectionWhite to off-white powder
SolubilityVisual (10 mg/mL in PBS, pH 7.4)Clear, colorless solution
Sequence VerificationLC-MS/MS Peptide Mapping100% sequence coverage

Each shipment includes a batch-specific Certificate of Analysis (CoA) documenting all quality parameters. Mass spectra and HPLC chromatograms are available upon request from qualified research institutions.

6. Available Configurations

HKPEPTIDE WORLDWIDE offers the full CJC-1295 Without DAC dosage range:

DosageSKUResearch Application
2 mgHKPW-CJC-NODAC-2MGPilot studies, binding assays, receptor pharmacology
5 mgHKPW-CJC-NODAC-5MGDose-response studies, pulse modeling, comparative pharmacology
10 mgHKPW-CJC-NODAC-10MGExtended protocols, multi-arm experimental designs

7. Tiered Wholesale Pricing

QuantityPrice Per VialSKU
1 Vial$95.00HKPW-CJC-NODAC-5MG-1
5 Vials$85.00/vial ($425 total)HKPW-CJC-NODAC-5MG-5
10 Vials$74.00/vial ($740 total)HKPW-CJC-NODAC-5MG-10
25+ VialsContact for bulk pricingHKPW-CJC-NODAC-5MG-BULK

All prices in USD. Institutional and academic discounts available upon verification. Bulk pricing for orders exceeding 25 vials — please contact our research support team.

8. Comparative Analysis: CJC-1295 Without DAC vs. With DAC vs. Native GRF(1-29)

PropertyCJC-1295 Without DACCJC-1295 With DACNative GRF(1-29) (Sermorelin)
Molecular Weight~3367 Da~3649 Da3358 Da
Plasma Half-Life~30 minutes~8 days<10 minutes
D-Ala² (DPP-4 Resistance)YesYesNo (native Ala)
Leu²⁷ (Oxidation Resistance)YesYesNo (native Met)
Albumin BindingNo (free peptide)Covalent (DAC linker)No
Receptor Activation ProfilePulsatileSustained/continuousUltra-short pulse
Best Research ApplicationPulse physiology, receptor kineticsLong-duration receptor occupancyBaseline comparator

9. Frequently Asked Questions

Q1: What is the difference between CJC-1295 With DAC and Without DAC?

The difference lies in a single structural modification: the Drug Affinity Complex (DAC). CJC-1295 With DAC incorporates a maleimidopropionic acid linker conjugated to Lys²⁰ that enables covalent, irreversible binding to the free thiol group of Cys³⁴ on serum albumin. This transforms the peptide from a short-acting compound (~30-minute half-life) to a long-acting compound (~8-day half-life). The core 29-amino acid sequence with four stabilizing substitutions is identical in both variants.

Q2: What solvent should I use to reconstitute CJC-1295 Without DAC 5 mg?

For most in vitro applications, reconstitute in sterile phosphate-buffered saline (PBS, pH 7.4) or cell culture-grade water. For preparation of concentrated stock solutions (1-10 mM), use sterile DMSO. Avoid vigorous vortexing; gentle swirling is sufficient for dissolution. Aliquot and store at -20°C for long-term storage or 2-8°C for short-term use (≤30 days). Do not subject to repeated freeze-thaw cycles.

Q3: Why choose the 5 mg format over 2 mg or 10 mg?

The 5 mg format provides the optimal balance for laboratories conducting systematic dose-response studies, pulse-frequency modeling, and comparative pharmacology experiments. It contains sufficient material for 8-12 point dose-response curves with triplicate measurements, or for multi-arm experimental designs comparing multiple GHRH analogues simultaneously, while remaining cost-efficient for routine research use.

Q4: Is a Certificate of Analysis provided?

Yes. Every shipment includes a batch-specific Certificate of Analysis (CoA) documenting: HPLC purity (≥99%), molecular weight confirmation by mass spectrometry, peptide content by amino acid analysis, TFA content, water content, endotoxin levels, and visual appearance.

Q5: Can CJC-1295 Without DAC be used in combination with GHRP peptides?

Yes, the combination of CJC-1295 Without DAC (a GHRH-R agonist) with GHS-R1a agonists such as GHRP-2, GHRP-6, or Ipamorelin is a well-established research paradigm for studying functional synergism between the two complementary pathways that regulate somatotroph GH secretion. The GHRH-R and GHS-R1a pathways converge on the somatotroph cell, producing supra-additive cAMP accumulation and GH release when co-activated. HKPEPTIDE WORLDWIDE offers a pre-formulated CJC-1295 Without DAC 5 mg + Ipamorelin 10 mg research blend for laboratories conducting these combination studies.

10. References & Further Reading

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352682
  2. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PMID: 15790728
  3. Frohman LA, Kineman RD, Kamegai J, et al. Secretagogues and the somatotrope: signaling and proliferation. Recent Prog Horm Res. 2000;55:269-290. PMID: 11036941
  4. Mayo KE, Miller LJ, Bataille D, et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003;55(1):167-194. PMID: 12615957
  5. Müller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999;79(2):511-607. PMID: 10221989
  6. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. PMID: 9861545
  7. Veldhuis JD, Anderson SM, Shah N, et al. Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion. Endocr Rev. 2001;22(6):789-816. PMID: 11739333
  8. Ling N, Baird A, Wehrenberg WB, et al. Isolation and characterization of the growth hormone releasing factor from a human pancreatic tumor. Biochem Biophys Res Commun. 1984;122(1):304-310. PMID: 6087804
  9. Thorner MO, Perryman RL, Cronin MJ, et al. Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest. 1982;70(5):965-977. PMID: 6290539
  10. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. PMID: 6425043

11. Compliance Statement

This product is manufactured for research purposes only and is not intended for human or veterinary diagnostic, therapeutic, or clinical applications. By purchasing CJC-1295 Without DAC 5 mg from HKPEPTIDE WORLDWIDE, the buyer affirms that:

  • The product will be used exclusively in a qualified research laboratory setting
  • All personnel handling this product are appropriately trained in laboratory safety and peptide handling protocols
  • The purchasing institution maintains all required permits, licenses, and regulatory approvals for research involving GHRH analogues
  • The product will not be resold, redistributed, or diverted for any purpose other than bona fide scientific research
  • The buyer acknowledges that this product is not FDA-approved for human or veterinary use

HKPEPTIDE WORLDWIDE reserves the right to request documentation verifying research credentials prior to order fulfillment.

Related Research & Resources

ResourceDescription
Healing Regenerative Peptides HubComplete research overview & methodology hub
Cjc 1295 With Dac 10 Mgin Vitro ResearchRelated research peptide product
Cjc 1295 With Dac 2 Mg Laboratory ResearRelated research peptide product
Why Muscle Growth Peptide Research Is ExpandingLatest research insights & methodology

View Complete Research Guide »